<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  <head>
    <meta charset="utf-8" />
<meta property="og:site_name" content="Vertex Pharmaceuticals" />
<meta property="og:type" content="website" />
<meta property="og:url" content="https://investors.vrtx.com/press-releases" />
<meta property="og:title" content="Press Releases | Vertex Pharmaceuticals" />
<meta property="og:description" content="The Investor Relations website contains information about Vertex Pharmaceuticals&#039;s business for stockholders, potential investors, and financial analysts." />
<meta name="Generator" content="Drupal 10 (https://www.drupal.org)" />
<meta name="MobileOptimized" content="width" />
<meta name="HandheldFriendly" content="true" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<link rel="icon" href="/sites/g/files/knoqqb74911/files/favicon.ico" type="image/vnd.microsoft.icon" />
<link rel="alternate" hreflang="en" href="https://investors.vrtx.com/press-releases" />
<link rel="canonical" href="https://investors.vrtx.com/press-releases" />
<link rel="shortlink" href="https://investors.vrtx.com/node/5816" />

    <title>Press Releases | Vertex Pharmaceuticals</title>
    <link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_1HvT-90as-e3CXVWo_1w4S2XTy309NZf7XoB6NbSpLQ.css?delta=0&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_Irk1fXP27BWbV6Mh5txGirKi1dfzWYXgLu8LcVhc-H0.css?delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Arimo:400,400italic,700,300italic" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Poiret+One" />
<link rel="stylesheet" media="all" href="//fonts.googleapis.com/css?family=Josefin+Slab:400,700,600,300" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_WF_WjdFnydexFLH-q6EV4RnXpbWPAYGc92V0TcW0t5g.css?delta=5&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="print" href="/sites/g/files/knoqqb74911/files/css/css_BafFCdsxiUI1wldlRvpIN5iLHxcBJGqNdV_v3x4wwU4.css?delta=6&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />
<link rel="stylesheet" media="all" href="/sites/g/files/knoqqb74911/files/css/css_rnf9BGrG97ZF8sypxyVluZjd7arGQ8x7Upxx8ceBe3g.css?delta=7&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVjUEKwzAMBD9kYppLnyNkW6QishRkJ6W_r5NboJdelmUYdpUdKvpKHQp2hCSW11gJFZyy1Uo6OJtCfqH3oD99VJRP6-BD1QUS-h96g45JKGRzisX3DWUqjGJLaMOiGhM2uqbOEs_C2bTdUTeTcXzBjcv8eM7RDnLnQuFgerd45VSt7EJfT5phrw" />

    <script src="/core/assets/vendor/modernizr/modernizr.min.js?v=3.11.7"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_zcZJg2ceexb8o86eQ2I6FQDMa0-CSF5vKxCHlcH4HzE.js?scope=header&amp;delta=1&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- OneTrust Cookies Consent Notice start for vrtx.com -->
<script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-document-language="true" type="text/javascript" charset="UTF-8" data-domain-script="55293c39-90c9-481e-be5a-a536e7236802" ></script>
<script type="text/javascript">
function OptanonWrapper() {
    var countryCode = OneTrust.getGeolocationData().country
    dataLayer.push({event:"GACountry", OneTrustCountryCode: countryCode})
}
</script>
<!-- OneTrust Cookies Consent Notice end for vrtx.com -->

<!-- Google Analytics Code -->
<script type="text/plain" class="optanon-category-C0002">
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
    m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})
  (window,document,'script','//www.google-analytics.com/analytics.js','ga');
                                
  ga('create', 'UA-709045-2', 'auto');
  ga('send', 'pageview');
</script>

<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-60HPP96Z4B" type="text/plain" class="optanon-category-C0002"></script>
<script type="text/plain" class="optanon-category-C0002"> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-60HPP96Z4B'); </script> 


<!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='https://analytics.imirwin.com/js/container_rVlDBFll.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-landing-page nir-node--5816 path-node page-node-type-nir-landing-page">
    <div id="skip">
      <a class="visually-hidden focusable skip-link" href="#main-menu">
        Skip to main navigation
      </a>
    </div>
    
      <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas>
    

<a href="#skip-to-content" class="hide-txt">Skip to Content</a>

<div class="off-canvas-wrapper">

    <div class="off-canvas-wrapper-inner" data-off-canvas-wrapper>

        <div class="off-canvas position-left reveal-for-large" id="my-info" data-off-canvas data-position="left">
            <div class="row column">
                <span class="logo">
                  <br>
                  <a href="//www.vrtx.com/">
                  <!-- animated logo -->
                   <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                  <br/>
                </span>

                <!-- nav -->
                <div class="row side-nav">
                    <div class="medium-8 medium-centered columns">
                        
    

<nav role="navigation" aria-labelledby="block-investorrelations-2-menu" class="block--system-menu-blockir block--system-menu-blockir--5816 block--sidebar-first--system-menu-block--ir block--sidebar-first--system-menu-block--ir--5816 block--e99e7083-5a42-4093-bf00-e1b8438402d1 block--e99e7083-5a42-4093-bf00-e1b8438402d1--5816 block block-menu navigation block-system-menublock menu--ir">
                        
    <h2 class="visually-hidden" id="block-investorrelations-2-menu">Investor Relations</h2>
    

                                            <ul data-block-uuid="e99e7083-5a42-4093-bf00-e1b8438402d1" class="vertical accordion-menu menu" data-accordion-menu>
                                        <li>
                <a href="/" target="" rel="" title="Main Investor Relations Page" data-drupal-link-system-path="&lt;front&gt;">Investors Home</a>
                            </li>
                                <li class="active-trail">
                <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816">News &amp; Events</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/press-releases" data-drupal-link-system-path="node/5816">Press Releases</a>
                            </li>
                                <li>
                <a href="/events-presentations" target="" rel="" data-drupal-link-system-path="node/24456">Events &amp; Presentations</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information" data-drupal-link-system-path="node/5916">Stock Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Quote &amp; Chart</a>
                            </li>
                                <li>
                <a href="/stock-information/historic-stock-lookup" data-drupal-link-system-path="node/5921">Historic Stock Lookup</a>
                            </li>
                                <li>
                <a href="/stock-information/investment-calculator" data-drupal-link-system-path="node/5926">Investment Calculator</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/stock-information/analyst-coverage" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                            </li>
                                <li>
                <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/financial-information/quarterly-results" data-drupal-link-system-path="node/5986">Quarterly Results</a>
                            </li>
                                <li>
                <a href="/financial-information/sec-filings" data-drupal-link-system-path="node/5876">SEC Filings</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="http://www.vrtx.com/our-company/leadership">Leadership</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-company/leadership/#board-of-directors">Board of Directors</a>
                            </li>
                                <li>
                <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Governance Documents</a>
                            </li>
                </ul>
    
                            </li>
                                <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                                                                <ul class="menu vertical">
                                        <li>
                <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">IR Contacts</a>
                            </li>
                                <li>
                <a href="/investor-faqs" target="" rel="" data-drupal-link-system-path="node/5941">FAQs</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/medicines/our-approved-medicines">Approved Medicines</a>
                            </li>
                                <li>
                <a href="http://www.vrtx.com/our-science/pipeline">Pipeline</a>
                            </li>
                                <li>
                <a href="/email-alerts" data-drupal-link-system-path="node/5946">Email Alerts</a>
                            </li>
                </ul>
    
                            </li>
                </ul>
    


    </nav>
<div id="block-stockquote-2" data-storage-id="node:31451:flexible_layout" class="block--market-data-block__stock-quote block--market-data-block__stock-quote--31451 block--sidebar-first--market-data-block__stock-quote block--sidebar-first--market-data-block__stock-quote--31451 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5 block--b23b16fc-7147-4bf3-bd29-2d329f8920d5--31451 block block-nir-market-data-block block-market-data-block__stock-quote">
  
    
      <div class='text-center'>
    <div class="quote-wrapper">
        <h5 class="text-center"></h5>
        <table class="stock-qupte">
            <tbody>
                                                                                                                                            <tr>
                    <td>Price</td>
                    <td></td>
                </tr>
                <tr>
                    <td>Change</td>
                    <td></td>
                </tr>
                                                </tbody>
        </table>
    </div>
</div>
<div class="stock-time">
     - </div>
  </div>

<div id="block-stockinfoattributionthomsonreuters" class="block--attribution-block__stock-info-attribution__thomson-reuters block--attribution-block__stock-info-attribution__thomson-reuters--31451 block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters block--sidebar-first--attribution-block__stock-info-attribution__thomson-reuters--31451 block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc block--34dc1e1a-9db4-405e-8e35-49f1041b8bfc--31451 block block-nir-attribution-block block-attribution-block__stock-info-attribution__thomson-reuters">
  
    
      <p>
  Data Provided by Refinitiv. Delayed ~15m.</p>

  </div>

<div id="block-widgetstockchart" class="block--nir-stock-chart block--nir-stock-chart--31451 block--sidebar-first--nir-stock-chart block--sidebar-first--nir-stock-chart--31451 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7 block--c72aa970-06ea-4045-b1b5-f20d0b0ba4f7--31451 block block-nir-stock-chart">
  
      <h2  id="block-nir-stock-chart">Nasdaq: VRTX</h2>
    
      
<img src="https://api.nasdaqomx.wallst.com/api/chart?display=mountain&symbol=VRTX.O-VRTX&scale=linear&duration=1yr&frequency=1dy&gridLine=n&bgColor=52247f&lineColor=ffffff&fillcolor=52247f|52247f&width=560&height=300&&amp;volume=0&amp;fontColor-C0=FFFFFF&amp;fontColor-C1=FFFFFF" width="560" height="300" ></img>

  </div>

                    </div>
                </div>

            </div>


                        <div class="stock text-center">
                  <div class="region region-sidebar-featured">
    <div id="block-shareholdertools-2" class="block--system-menu-blockshareholder-tools block--system-menu-blockshareholder-tools--31451 block--sidebar-featured--system-menu-block--shareholder-tools block--sidebar-featured--system-menu-block--shareholder-tools--31451 block--4121c46a-4fb3-40cf-a26e-3dc466a9248c block--4121c46a-4fb3-40cf-a26e-3dc466a9248c--31451 block block-system block-system-menu-blockshareholder-tools gcs-sidebar-block">
  
    
                    <ul data-block-uuid="4121c46a-4fb3-40cf-a26e-3dc466a9248c" class="tools">
          
                                              
        <li class="side-menu__item">
                    <a href="/email-alerts" title="Email Alerts" class="glyph-icon flaticon-alarm-1" target="">
            <span class="fa-stack">
            
                               <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/notifications.svg" alt="">
                
            </span>
          </a>

                  </li>
      
                                              
        <li class="side-menu__item">
                    <a href="/rss-news-feeds" title="RSS News Feeds" class="glyph-icon flaticon-newspaper" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/rss_feed.svg" alt="">

              
            </span>
          </a>

                  </li>
      
                                                
        <li class="side-menu__item">
                    <a href="/investor-feedback" title="Investor Feedback" class="glyph-icon flaticon-paper-plane" target="">
            <span class="fa-stack">
            
                              <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/email.svg" alt="">
              
            </span>
          </a>

                  </li>
          </ul>
  


  </div>

  </div>

            </div>
            




        </div> <!-- /off-canvas -->

        <div class="off-canvas-content"  id="skip-to-content" data-off-canvas-content>

            <div class="title-bar hide-for-large">
                <div class="title-bar-left">
                    <button class="menu-icon" type="button" data-open="my-info" aria-label="Menu button"></button>
                    <span class="title-bar-title"><!-- Menu --></span>
                </div>
                <span class="logo">
                  <a href="//www.vrtx.com/">
                    <!-- static logo -->
                    <img class="logo-light" src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/client/images/white-vector.svg" alt="Vertex Pharmaceuticals">
                                        </a>
                </span>
            </div>

            <div class="callout primary">
                <div class="row">
                    <h1 class="header-title">

                                            News & Events
                                        </h1>

                                    </div>
            </div>

            

            


                            <div id="ndq-content" class="row ndq-5816 inside-pages large-12 columns">
                    <h2 class="h2content-heading">

                                                    Press Releases
                                            </h2>



                      <div class="region region-content">
    <div id="block-nir-pid2172-websitenoticeblock" class="block--website-notice-block block--website-notice-block--5816 block--content--website-notice-block block--content--website-notice-block--5816 block--dd8b7d55-3418-4333-8560-aa0535832f20 block--dd8b7d55-3418-4333-8560-aa0535832f20--5816 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2172-content" class="block--system-main-block block--system-main-block--5816 block--content--system-main-block block--content--system-main-block--5816 block--32fb46b7-e82f-437f-b00f-4734f5697096 block--32fb46b7-e82f-437f-b00f-4734f5697096--5816 block block-system block-system-main-block">
  
    
      <article class="node node--type-nir_landing_page node--view-mode-full clearfix">
  
      <h1>
              Press Releases
          </h1>
    

  <div>
    
<div class="panel-display boxton clearfix " >

  <div class="container-fluid">
    <div class="row">
      <div class="columns large-12 radix-layouts-content panel-panel">
        <div class="panel-panel-inner">
          <div class="block-region-contentmain">
<div class="block--search-form block--search-form--5816 block--contentmain--search-form block--contentmain--search-form--5816 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7 block--69c1a507-53a5-47e3-8700-d9cecb7ecae7--5816 block block-nir-search block-search-form">
  
    
      <form data-block-uuid="69c1a507-53a5-47e3-8700-d9cecb7ecae7" action="/search" method="get" accept-charset="UTF-8">
  <div class="js-form-item form-item js-form-type-search form-item-query js-form-item-query form-no-label">
        <input type="search" name="query" size="60" maxlength="128" placeholder="What are you looking for today?" class="form-search required" required="required" aria-required="true" />

        </div>
<input type="hidden" name="f[0]" value="type:nir_news" />
<input type="submit" name="op" value="Search" class="button button--primary js-form-submit form-submit" />

</form>

  </div>

<div class="views-element-container block--views-blockwidget-news-table block--views-blockwidget-news-table--5816 block--contentmain--views-block--widget-news-table block--contentmain--views-block--widget-news-table--5816 block--c9e9f210-6659-4313-bbd1-f20963e32837 block--c9e9f210-6659-4313-bbd1-f20963e32837--5816 block block-views block-views-blockwidget-news-table">
  
    
      <div data-block-uuid="c9e9f210-6659-4313-bbd1-f20963e32837"><div class="view view-widget-news view-id-widget_news view-display-id-table js-view-dom-id-d96d9cf9de3bb3905faaffc57580b3068f8400739ddcf325baa4f5b96d2ba757">
  
    
      
      <div class="view-content">
      <table class="nirtable views-table views-view-table cols-3 collapse-table">
        <thead>
      <tr>
                                                  <th id="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date" scope="col"><a href="?items_per_page_toggle=1&amp;page=5&amp;order=field_nir_news_date&amp;sort=asc" title="sort by Date">Date</a></th>
                                                  <th id="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title" scope="col"><a href="?items_per_page_toggle=1&amp;page=5&amp;order=field_nir_news_title&amp;sort=asc" title="sort by Title and Summary">Title and Summary</a></th>
                                                  <th id="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format" scope="col">Additional Formats</th>
              </tr>
    </thead>
    <tbody>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-07-17T13:00:00Z" timezone="America/New_York" class="datetime">Jul 17, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-second-quarter-2019-financial-results-july-31" hreflang="en">Vertex to Announce Second-Quarter 2019 Financial Results on July 31</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jul. 17, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2019 financial results on Wednesday, July 31, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-second-quarter-2019-financial-results-july-31" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26276/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-06-21T18:30:00Z" timezone="America/New_York" class="datetime">Jun 21, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/fda-approves-symdekor-tezacaftorivacaftor-and-ivacaftor-treat" hreflang="en">FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -SYMDEKO is now approved for patients 6 years of age and older with two copies of the F508del mutation or one copy of a responsive mutation- -Vertex&#039;s third medicine approved to treat the underlying cause of CF in eligible patients in this age range- BOSTON --(BUSINESS WIRE)--Jun.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/fda-approves-symdekor-tezacaftorivacaftor-and-ivacaftor-treat" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26256/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-06-06T21:12:00Z" timezone="America/New_York" class="datetime">Jun 6, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-expands-new-disease-areas-and-enhances-gene-editing" hreflang="en">Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Provides Vertex with leading gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1- -CRISPR to receive an upfront payment of $175 million , with potential for additional milestone and royalty payments- -Exonics to be acquired for an
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-expands-new-disease-areas-and-enhances-gene-editing" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26231/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-06-04T12:00:00Z" timezone="America/New_York" class="datetime">Jun 4, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-data-ecfs-conference-potential-impact-early" hreflang="en">Vertex to Present Data at ECFS Conference on Potential Impact of Early Treatment and Long-Term Treatment with CFTR Modulators on the Underlying Cause of CF</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jun. 4, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from six scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 42 nd European Cystic Fibrosis Conference , taking place June
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-data-ecfs-conference-potential-impact-early" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26181/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-05-30T12:00:00Z" timezone="America/New_York" class="datetime">May 30, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-selects-triple-combination-regimen-vx-445-tezacaftor-and" hreflang="en">Vertex Selects Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor to Submit for Global Regulatory Approvals in Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Mean absolute improvement in ppFEV 1 of 14.3 percentage points from baseline through week 24 of treatment compared to placebo (p
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-selects-triple-combination-regimen-vx-445-tezacaftor-and" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26176/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-05-15T12:30:00Z" timezone="America/New_York" class="datetime">May 15, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-kymera-therapeutics-establish-strategic-collaboration" hreflang="en">Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Multi-year collaboration leveraging Kymera’s proprietary targeted protein degradation platform to develop novel medicines- -Kymera to receive $70 million upfront, including equity investment, and potential additional milestone and royalty payments for up to six programs in the collaboration-
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-kymera-therapeutics-establish-strategic-collaboration" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26126/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-04-30T20:01:00Z" timezone="America/New_York" class="datetime">Apr 30, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-first-quarter-2019-financial-results" hreflang="en">Vertex Reports First-Quarter 2019 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - First-quarter 2019 product revenues of $857 million , a 34% increase compared to $638 million in 2018- - First-quarter 2019 GAAP operating income increased 115% to $277 million ; non-GAAP operating income increased 81% to $377 million - - On track to choose best triple combination regimen in Q2
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-first-quarter-2019-financial-results" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26081/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-04-30T12:30:00Z" timezone="America/New_York" class="datetime">Apr 30, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-first-and-only-cftr-modulator" hreflang="en">FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Opportunity to treat the underlying cause of CF earlier than ever before- -Safety data from Phase 3 ARRIVAL study support treatment with KALYDECO in children ages six to 
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-first-and-only-cftr-modulator" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26071/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-04-16T11:00:00Z" timezone="America/New_York" class="datetime">Apr 16, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-fda-fast-track-0" hreflang="en">CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  ZUG, Switzerland and CAMBRIDGE and BOSTON, Mass. – April 16, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-fda-fast-track-0" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26041/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-04-12T12:00:00Z" timezone="America/New_York" class="datetime">Apr 12, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-first-quarter-2019-financial-results-april-30" hreflang="en">Vertex to Announce First-Quarter 2019 Financial Results on April 30</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Apr. 12, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2019 financial results on Tuesday, April 30, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-first-quarter-2019-financial-results-april-30" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26026/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-04-02T12:00:00Z" timezone="America/New_York" class="datetime">Apr 2, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-appoints-charles-wagner-chief-financial-officer" hreflang="en">Vertex Appoints Charles Wagner as Chief Financial Officer</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Apr. 2, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief Financial Officer (CFO), effective April 10, 2019 . Mr. Wagner will report directly to Vertex Chairman,
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-appoints-charles-wagner-chief-financial-officer" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26011/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-03-12T09:07:00Z" timezone="America/New_York" class="datetime">Mar 12, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-approval-symdekor-tezacaftorivacaftor-and" hreflang="en">Vertex Receives Approval for SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -A new treatment option for patients with two copies of the F508del mutation, the most common mutation in cystic fibrosis- -First medicine in Australia to treat the underlying cause of cystic fibrosis in patients who have certain mutations that result in residual CFTR function- BOSTON --(BUSINESS
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-approval-symdekor-tezacaftorivacaftor-and" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/26001/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-03-06T13:00:00Z" timezone="America/New_York" class="datetime">Mar 6, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/two-phase-3-studies-triple-combination-vx-445-tezacaftor-and" hreflang="en">Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Mean absolute improvement in ppFEV 1 of 13.8 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation (F/MF) compared to placebo (p
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/two-phase-3-studies-triple-combination-vx-445-tezacaftor-and" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25991/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-02-25T13:00:00Z" timezone="America/New_York" class="datetime">Feb 25, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-progress-clinical" hreflang="en">CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase 1/2 clinical trial of CTX001 for patients with sickle cell disease- ZUG, Switzerland and CAMBRIDGE and BOSTON, Mass., Feb.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-progress-clinical" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25986/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-02-21T21:01:00Z" timezone="America/New_York" class="datetime">Feb 21, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-appoints-lloyd-carney-its-board-directors" hreflang="en">Vertex Appoints Lloyd Carney to its Board of Directors</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Feb. 21, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Lloyd Carney has been appointed to its board of directors as an independent director. Mr. Carney is a prominent technology executive with experience leading innovative, high-growth
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-appoints-lloyd-carney-its-board-directors" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25941/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-02-14T14:04:00Z" timezone="America/New_York" class="datetime">Feb 14, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/positive-phase-3-study-tezacaftorivacaftor-combination-children" hreflang="en">Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Study met primary endpoint with a statistically significant improvement in absolute change in lung clearance index (LCI 2.5 ) through 8 weeks of tezacaftor/ivacaftor treatment- -Tezacaftor in combination with ivacaftor was generally well tolerated and safety data were consistent with previous
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/positive-phase-3-study-tezacaftorivacaftor-combination-children" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25931/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-02-05T21:01:00Z" timezone="America/New_York" class="datetime">Feb 5, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2018-financial" hreflang="en">Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Full-year 2018 CF product revenues of $3.04 billion , a 40% increase compared to $2.17 billion in 2017; fourth-quarter 2018 CF product revenues of $868 million - - Full-year 2018 GAAP operating income increased 415% to $635 million ; non-GAAP operating income increased 97% to $1.11 billion - -
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-full-year-and-fourth-quarter-2018-financial" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25791/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-01-28T14:17:00Z" timezone="America/New_York" class="datetime">Jan 28, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/health-canada-grants-market-authorization-kalydecor-ivacaftor" hreflang="en">Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) in Children Ages 12 to &lt;24 months with Certain Mutations in the CFTR Gene</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -KALYDECO is the first and only approved medicine in Canada to treat the underlying cause of cystic fibrosis in these young patients- BOSTON --(BUSINESS WIRE)--Jan. 28, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Market Authorization for
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/health-canada-grants-market-authorization-kalydecor-ivacaftor" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25776/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-01-23T21:05:00Z" timezone="America/New_York" class="datetime">Jan 23, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-departure-ian-smith-names-interim-cfo" hreflang="en">Vertex Announces Departure of Ian Smith, Names Interim CFO</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jan. 23, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ian Smith has been terminated as Chief Operating Officer and interim Chief Financial Officer (CFO) effective immediately. Mr. Smith’s termination is the result of personal behavior that
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-departure-ian-smith-names-interim-cfo" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25751/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-01-22T21:01:00Z" timezone="America/New_York" class="datetime">Jan 22, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-full-year-and-fourth-quarter-2018-financial" hreflang="en">Vertex to Announce Full-Year and Fourth-Quarter 2018 Financial Results on February 5</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jan. 22, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its full year and fourth quarter 2018 financial results on Tuesday, February 5, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-full-year-and-fourth-quarter-2018-financial" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25741/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-01-21T09:00:00Z" timezone="America/New_York" class="datetime">Jan 21, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-orkambir" hreflang="en">Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  Lumacaftor/ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis for approximately 1,500 children aged 2 to 5 with two copies of the F508del mutation LONDON --(BUSINESS WIRE)--Jan. 21, 2019-- Vertex Pharmaceuticals (Europe) Limited today
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-orkambir" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25731/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-01-04T12:17:00Z" timezone="America/New_York" class="datetime">Jan 4, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-fda-fast-track" hreflang="en">CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Jan. 04, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics&amp;nbsp;(NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-fda-fast-track" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25701/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-01-03T13:00:00Z" timezone="America/New_York" class="datetime">Jan 3, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-arbor-biotechnologies-establish-collaboration" hreflang="en">Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Multi-year research collaboration funded by Vertex using Arbor’s proprietary research platform to enhance efforts in developing gene-editing therapies in five diseases- -Arbor to receive up-front cash payment and convertible note investment, research funding, and potential for additional
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-arbor-biotechnologies-establish-collaboration" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25691/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2019-01-02T21:01:00Z" timezone="America/New_York" class="datetime">Jan 2, 2019</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-jp-morgan-healthcare-conference-january-7" hreflang="en">Vertex to Present at the J.P. Morgan Healthcare Conference on January 7</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jan. 2, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:30 p.m. ET ( 11:30 a.m. PT ). The audio portion of management’s remarks can be accessed
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-jp-morgan-healthcare-conference-january-7" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25681/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-12-19T17:04:00Z" timezone="America/New_York" class="datetime">Dec 19, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-it-will-submit-cystic-fibrosis-medicines" hreflang="en">Vertex Announces it will Submit Cystic Fibrosis Medicines ORKAMBI® (lumacaftor/ivacaftor) as well as SYMKEVI® (tezacaftor/ivacaftor) to be Used in Combination with ivacaftor, to the Scottish Medicines Consortium for Appraisal</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - If accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland , eligible patients could have access to these precision cystic fibrosis medicines in 2019 - - While the SMC reviews the submissions, clinicians can apply for access to these CF medicines via the PACS Tier 2
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-it-will-submit-cystic-fibrosis-medicines" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25641/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-12-18T13:30:00Z" timezone="America/New_York" class="datetime">Dec 18, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-positive-phase-2-data-third-proof-concept-study" hreflang="en">Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Treatment with the NaV1.8 inhibitor VX-150 showed significant relief of pain in patients with small fiber neuropathy and was generally well tolerated- -Third positive Phase 2 proof-of-concept study for VX-150 further validates the potential role of NaV1.8 inhibition for the treatment of multiple
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-positive-phase-2-data-third-proof-concept-study" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25631/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-12-13T13:00:00Z" timezone="America/New_York" class="datetime">Dec 13, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/health-canada-grants-market-authorization-orkambir" hreflang="en">Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - ORKAMBI is the first medicine in Canada to treat the underlying cause of CF in young children with two copies of the F508del mutation - BOSTON --(BUSINESS WIRE)--Dec. 13, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that Health Canada has granted Market Authorization
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/health-canada-grants-market-authorization-orkambir" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25621/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-11-29T08:02:00Z" timezone="America/New_York" class="datetime">Nov 29, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor" hreflang="en">Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) to Treat Patients with Cystic Fibrosis Aged 12 to &lt;24 months with Certain Mutations in the CFTR Gene</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in these young patients LONDON --(BUSINESS WIRE)--Nov. 29, 2018-- Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-european-commission-approval-kalydecor" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25606/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-11-27T13:00:00Z" timezone="America/New_York" class="datetime">Nov 27, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/two-phase-3-studies-triple-combination-vx-659-tezacaftor-and" hreflang="en">Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Mean absolute improvement in ppFEV 1 of 14.0 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation compared to placebo (p
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/two-phase-3-studies-triple-combination-vx-659-tezacaftor-and" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25601/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-11-16T12:57:00Z" timezone="America/New_York" class="datetime">Nov 16, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-orkambir" hreflang="en">Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - If approved, lumacaftor/ivacaftor will be the first medicine in Europe to treat the underlying cause of cystic fibrosis for approximately 1,500 young children with two copies of the F508del mutation - LONDON --(BUSINESS WIRE)--Nov. 16, 2018-- Vertex Pharmaceuticals (Europe) Limited today
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-orkambir" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25571/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-11-01T08:00:00Z" timezone="America/New_York" class="datetime">Nov 1, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-european-authorization-third-cystic-fibrosis" hreflang="en">Vertex Announces European Authorization for Third Cystic Fibrosis Medicine SYMKEVI® (tezacaftor/ivacaftor), to be used in combination with ivacaftor (KALYDECO®), for People with CF Aged 12 and Older with Certain Mutations in the CFTR gene</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - A new treatment option for patients with two copies of the F508del mutation, the most common mutation in cystic fibrosis - - First medicine in the EU to treat the CFTR protein defect in patients who have one copy of the F508del mutation and one copy of one of 14 mutations that result in residual
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-european-authorization-third-cystic-fibrosis" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25531/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-10-24T20:01:00Z" timezone="America/New_York" class="datetime">Oct 24, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-third-quarter-2018-financial-results" hreflang="en">Vertex Reports Third-Quarter 2018 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Third-quarter 2018 total CF product revenues of $783 million , a 42% increase compared to $550 million in the third quarter of 2017- -Company reiterates full-year 2018 total CF product revenue guidance of $2.9 to $3.0 billion ; reiterates full-year 2018 combined non-GAAP R&amp;amp;D and SG&amp;amp;A expense
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-third-quarter-2018-financial-results" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25516/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-10-19T11:54:00Z" timezone="America/New_York" class="datetime">Oct 19, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-kalydecor" hreflang="en">Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to &lt;24 months With Certain Mutations in the CFTR Gene </a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic fibrosis for these young children LONDON --(BUSINESS WIRE)--Oct. 19, 2018-- Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-kalydecor" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25501/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-10-18T15:45:00Z" timezone="America/New_York" class="datetime">Oct 18, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-data-presented-north-american-cystic-fibrosis-conference" hreflang="en">Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Phase 2 results of VX-659 and VX-445 triple combination regimens concurrently published in The New England Journal of Medicine - - Phase 3 ARRIVAL data support treating the underlying cause of cystic fibrosis with KALYDECO ® (ivacaftor) as early as six months of age - - Patient-reported outcomes
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-data-presented-north-american-cystic-fibrosis-conference" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25496/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-10-16T20:01:00Z" timezone="America/New_York" class="datetime">Oct 16, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-third-quarter-2018-financial-results-october-24" hreflang="en">Vertex to Announce Third Quarter 2018 Financial Results on October 24</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Oct. 16, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-third-quarter-2018-financial-results-october-24" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25481/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-10-10T20:00:00Z" timezone="America/New_York" class="datetime">Oct 10, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-fda-has-lifted-clinical" hreflang="en">CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  ZUG, Switzerland &amp;nbsp; and &amp;nbsp; BOSTON &amp;nbsp; and &amp;nbsp; CAMBRIDGE, Mass. , &amp;nbsp; Oct. 10, 2018 &amp;nbsp; (GLOBE NEWSWIRE) -- &amp;nbsp; CRISPR Therapeutics&amp;nbsp; (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and &amp;nbsp; Vertex Pharmaceuticals Incorporated &amp;nbsp; (NASDAQ:VRTX)
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4041&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Other</small></a>
  </div>
    </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/crispr-therapeutics-and-vertex-announce-fda-has-lifted-clinical" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25471/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-10-01T12:02:00Z" timezone="America/New_York" class="datetime">Oct 1, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-access-contract-denmark-current-and-future" hreflang="en">Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - First-of-its-kind contract with the Danish pharmaceutical and procurement organization, Amgros, is effective from today - - Vertex also announces reimbursement in Austria for ORKAMBI ® (lumacaftor/ivacaftor) to treat patients ages 6 through 11 with two copies of the F508del mutation - LONDON
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-access-contract-denmark-current-and-future" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25441/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-09-11T20:01:00Z" timezone="America/New_York" class="datetime">Sep 11, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-present-morgan-stanley-healthcare-conference-september-14" hreflang="en">Vertex to Present at the Morgan Stanley Healthcare Conference on September 14</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Sep. 11, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Friday, September 14, 2018 at 12:15 p.m. ET . The audio portion of management’s remarks will be available live
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-present-morgan-stanley-healthcare-conference-september-14" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25431/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-09-10T13:11:00Z" timezone="America/New_York" class="datetime">Sep 10, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-appoints-katharine-jensen-head-corporate-social" hreflang="en">Vertex Appoints Katharine Jensen as Head of Corporate Social Responsibility</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -- Ms. Jensen to oversee global CSR efforts and lead The Vertex Foundation -- BOSTON --(BUSINESS WIRE)--Sep. 10, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Katharine Jensen has been appointed Head of Corporate Social Responsibility (CSR). In this role, Ms.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-appoints-katharine-jensen-head-corporate-social" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25426/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-09-06T12:00:00Z" timezone="America/New_York" class="datetime">Sep 6, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-completes-enrollment-two-phase-3-studies-vx-659-triple" hreflang="en">Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Data expected in late 2018 from Phase 3 studies of VX-659, tezacaftor and ivacaftor in people with one F508del mutation and one minimal function mutation and in people with two F508del mutations- -Enrollment of two Phase 3 studies of VX-445 in triple combination with tezacaftor and ivacaftor
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-completes-enrollment-two-phase-3-studies-vx-659-triple" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25421/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-09-03T07:00:00Z" timezone="America/New_York" class="datetime">Sep 3, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announces-reimbursement-agreement-australia-orkambir" hreflang="en">Vertex Announces Reimbursement Agreement in Australia for ORKAMBI® (lumacaftor/ivacaftor) for People with Cystic Fibrosis Ages Six Years and Older with Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Approximately 1,300 patients in Australia join the thousands of patients worldwide who already have access to lumacaftor/ivacaftor - - A pathway to access for future Vertex CF medicine, tezacaftor/ivacaftor, has also been established - LONDON --(BUSINESS WIRE)--Sep.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announces-reimbursement-agreement-australia-orkambir" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25416/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-08-30T06:00:00Z" timezone="America/New_York" class="datetime">Aug 30, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-and-genomics-plc-establish-collaboration-use-human" hreflang="en">Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  Multi-year collaboration combines expertise in genomics, machine learning and drug discovery to identify novel targets for innovative medicines BOSTON &amp;amp; OXFORD, United Kingdom --(BUSINESS WIRE)--Aug. 30, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-and-genomics-plc-establish-collaboration-use-human" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25406/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-08-23T07:00:00Z" timezone="America/New_York" class="datetime">Aug 23, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-appoints-ludovic-fenaux-senior-vice-president" hreflang="en">Vertex Appoints Ludovic Fenaux as Senior Vice President, International Commercial Operations</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  – Ludovic Fenaux to lead Vertex’s expanding International organization – – Simon Bedson announces retirement – LONDON --(BUSINESS WIRE)--Aug. 23, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ludovic Fenaux has been appointed Senior Vice President, International
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-appoints-ludovic-fenaux-senior-vice-president" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25401/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-08-20T07:00:00Z" timezone="America/New_York" class="datetime">Aug 20, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-positive-pbac-recommendation-reimbursement" hreflang="en">Vertex Receives a Positive PBAC Recommendation for Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - PBAC recommendation moves approximately 1,300 patients in Australia closer to access to lumacaftor/ivacaftor and Vertex is now working with the Australian Government to finalize a reimbursement agreement as soon as possible - LONDON --(BUSINESS WIRE)--Aug.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-positive-pbac-recommendation-reimbursement" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25396/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-08-16T14:04:00Z" timezone="America/New_York" class="datetime">Aug 16, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-awards-two-college-students-full-scholarships-university" hreflang="en">Vertex Awards Two College Students Full Scholarships to the University of Massachusetts</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -- Boston Public High School Students Nora Nguyen and Sonny Mei Receive Vertex Science Leaders Scholarship to Pursue STEAM Degrees at UMass -- BOSTON --(BUSINESS WIRE)--Aug. 16, 2018-- Vertex today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-awards-two-college-students-full-scholarships-university" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25391/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-08-15T19:29:00Z" timezone="America/New_York" class="datetime">Aug 15, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-first-and-only-medicine-treat" hreflang="en">FDA Approves KALYDECO® (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to &lt;24 Months with Certain Mutations in the CFTR Gene </a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Data from Phase 3 ARRIVAL study support treatment with KALYDECO in children ages 12 to
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/fda-approves-kalydecor-ivacaftor-first-and-only-medicine-treat" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25386/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-08-07T19:48:00Z" timezone="America/New_York" class="datetime">Aug 7, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/fda-approves-orkambir-lumacaftorivacaftor-first-medicine-treat" hreflang="en">FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  - Approximately 1,300 people in the U.S. ages 2 through 5 years have two copies of the F508del mutation, the most common genetic form of the disease - BOSTON --(BUSINESS WIRE)--Aug. 7, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S.
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/fda-approves-orkambir-lumacaftorivacaftor-first-medicine-treat" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25376/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-07-27T14:22:00Z" timezone="America/New_York" class="datetime">Jul 27, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-symkevir" hreflang="en">Vertex Receives European CHMP Positive Opinion for SYMKEVI® (tezacaftor/ivacaftor) for People with Cystic Fibrosis Aged 12 and Older with Certain Mutations in the CFTR Gene</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  If approved, SYMKEVI ® (tezacaftor/ivacaftor) will be Vertex’s third medicine to treat the CFTR protein defect in patients with cystic fibrosis – a rare life-shortening disease LONDON --(BUSINESS WIRE)--Jul. 27, 2018-- Vertex Pharmaceuticals (Europe) Limited , today announced that the European
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4031&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>General Business</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-receives-european-chmp-positive-opinion-symkevir" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25351/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-07-25T20:01:00Z" timezone="America/New_York" class="datetime">Jul 25, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-reports-second-quarter-2018-financial-results" hreflang="en">Vertex Reports Second-Quarter 2018 Financial Results</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  -Second-quarter 2018 total CF product revenues of $750 million , a 46% increase compared to $514 million in the second quarter of 2017- -Company increases full-year 2018 total CF product revenue guidance to $2.9 to $3.0 billion ; reiterates full-year 2018 combined non-GAAP R&amp;amp;D and SG&amp;amp;A expense
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4021&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Financial</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-reports-second-quarter-2018-financial-results" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25331/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
          <tr>
                                                                                        <td headers="view-field-nir-news-date-table-column" class="views-field views-field-field-nir-news-date"><a href="#" class="summary-toggle nir-news-widget-summary-toggle-date"><span>Toggle Summary</span></a><time datetime="2018-07-12T20:01:00Z" timezone="America/New_York" class="datetime">Jul 12, 2018</time>          </td>
                                                                                        <td headers="view-field-nir-news-title-table-column" class="views-field views-field-field-nir-news-title">
<a href="/news-releases/news-release-details/vertex-announce-second-quarter-2018-financial-results-july-25" hreflang="en">Vertex to Announce Second Quarter 2018 Financial Results on July 25</a>
<div class="nir-news-table-teaser summary-hidden">
  <summary>
  BOSTON --(BUSINESS WIRE)--Jul. 12, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2018 financial results on Wednesday, July 25, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .
  </summary>
    <div class="ndq-releasetype">
    <a href="/press-releases?field_nir_news_category_target_id%5B%5D=4046&field_nir_news_date_value%5Bmin%5D=#views-exposed-form-widget-news-table"><small>Webcasts</small></a>
  </div>
  </div>
          </td>
                                                                                        <td headers="view-field-nir-news-supp-format-table-column" class="views-field views-field-field-nir-news-supp-format">
<span class="html-link"><a href="/news-releases/news-release-details/vertex-announce-second-quarter-2018-financial-results-july-25" target="_self">View HTML</a></span>
<div class="file-link pdf-file-link">
  <span class="file file--mime-application-pdf file--application-pdf"><a href="/node/25281/pdf" type="application/pdf" target="_blank">PDF Version</a></span>
</div>          </td>
              </tr>
      </tbody>
</table>

    </div>
  
        <nav class="pager" role="navigation" aria-labelledby="pagination-heading">
    <h4 id="pagination-heading" class="visually-hidden">Pagination</h4>
    <ul class="pager__items js-pager__items">
                    <li class="pager__item pager__item--first">
          <a href="?items_per_page_toggle=1&amp;page=0" title="Go to first page">
            <span class="visually-hidden">First page</span>
            <span aria-hidden="true">First</span>
          </a>
        </li>
                          <li class="pager__item pager__item--previous">
          <a href="?items_per_page_toggle=1&amp;page=4" title="Go to previous page" rel="prev">
            <span class="visually-hidden">Previous page</span>
            <span aria-hidden="true">Previous</span>
          </a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation" aria-hidden="true">&hellip;</li>
                          <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=4" title="Go to page 5">
            <span class="visually-hidden">
              Page
            </span>5</a>
        </li>
              <li class="pager__item is-active">
                                          <a href="?items_per_page_toggle=1&amp;page=5" title="Current page" aria-current="page">
            <span class="visually-hidden">
              Current page
            </span>6</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=6" title="Go to page 7">
            <span class="visually-hidden">
              Page
            </span>7</a>
        </li>
              <li class="pager__item">
                                          <a href="?items_per_page_toggle=1&amp;page=7" title="Go to page 8">
            <span class="visually-hidden">
              Page
            </span>8</a>
        </li>
                          <li class="pager__item pager__item--ellipsis" role="presentation" aria-hidden="true">&hellip;</li>
                          <li class="pager__item pager__item--next">
          <a href="?items_per_page_toggle=1&amp;page=6" title="Go to next page" rel="next">
            <span class="visually-hidden">Next page</span>
            <span aria-hidden="true">Next</span>
          </a>
        </li>
                          <li class="pager__item pager__item--last">
          <a href="?items_per_page_toggle=1&amp;page=16" title="Go to last page">
            <span class="visually-hidden">Last page</span>
            <span aria-hidden="true">Last</span>
          </a>
        </li>
          </ul>
  </nav>

  
          <div class="view-footer">
          <div class="results-summary">Displaying 251 - 300 of 836 results</div>
        </div>
    </div>
</div>

  </div>
</div>
        </div>
      </div>
    </div>
  </div>

</div><!-- /.boxton -->

  </div>
</article>

  </div>

  </div>

                </div>
            

            


            <footer>
                                <div class="column footer-sitemap">
                    <div class="row small-up-1 medium-up-4 large-up-4 flexy">
                        

<div role="navigation" aria-labelledby="block-footercol1-menu" id="block-footercol1" class="block--system-menu-blockfooter-col-1 block--system-menu-blockfooter-col-1--5816 block--footer-first--system-menu-block--footer-col-1 block--footer-first--system-menu-block--footer-col-1--5816 block--da449755-c1be-4e93-bf75-4db21af16447 block--da449755-c1be-4e93-bf75-4db21af16447--5816 block block-menu navigation block-system-menublock menu--footer-col-1 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol1-menu" class="lead">Footer Col 1</p>
    

                              <ul data-block-uuid="da449755-c1be-4e93-bf75-4db21af16447" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/press-releases" target="" rel="" data-drupal-link-system-path="node/5816">News &amp; Events</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information" target="" rel="" data-drupal-link-system-path="node/5916">Stock Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/stock-information/analyst-coverage" target="" rel="" data-drupal-link-system-path="node/5896">Analyst Coverage</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol2-menu" id="block-footercol2" class="block--system-menu-blockfooter-col-2 block--system-menu-blockfooter-col-2--31451 block--footer-first--system-menu-block--footer-col-2 block--footer-first--system-menu-block--footer-col-2--31451 block--bdf059f5-091d-492a-8531-746af0f478ff block--bdf059f5-091d-492a-8531-746af0f478ff--31451 block block-menu navigation block-system-menublock menu--footer-col-2 small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-footercol2-menu" class="lead">Footer Col 2</p>
    

                              <ul data-block-uuid="bdf059f5-091d-492a-8531-746af0f478ff" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="/financial-information/quarterly-results" target="" rel="" data-drupal-link-system-path="node/5986">Financial Information</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/corporate-governances" target="" rel="" data-drupal-link-system-path="node/24511">Corporate Governance</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="/contact-us" target="" rel="" data-drupal-link-system-path="node/5981">Investor Resources</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-footercol3-menu" id="block-footercol3" class="block--system-menu-blockfooter-col-3 block--system-menu-blockfooter-col-3--31451 block--footer-first--system-menu-block--footer-col-3 block--footer-first--system-menu-block--footer-col-3--31451 block--7e76016d-878b-43d2-a4f3-4289a342a22d block--7e76016d-878b-43d2-a4f3-4289a342a22d--31451 block block-menu navigation block-system-menublock menu--footer-col-3 small-6 large-3 columns">
            
    <p id="block-footercol3-menu" class="lead">Vertex Websites</p>
    

                              <ul data-block-uuid="7e76016d-878b-43d2-a4f3-4289a342a22d" class="menu vertical">
                                                                        <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/">Global</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.fr/">France</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.de/">Germany</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.ca/">Canada</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtxpharma.co.uk/">United Kingdom</a>
                              </li>
                                                                    <li class="notSocialLink side-menu__item">
                          <a href="https://www.vrtx.com/en-us">United States</a>
                              </li>
          </ul>
  


    </div>


<div role="navigation" aria-labelledby="block-socialmedia-menu" id="block-socialmedia" class="block--system-menu-blocksocial-media block--system-menu-blocksocial-media--31451 block--footer-first--system-menu-block--social-media block--footer-first--system-menu-block--social-media--31451 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1 block--5d1642a9-9f5b-4bed-9f56-6157a76875d1--31451 block block-menu navigation block-system-menublock menu--social-media small-6 large-3 columns">
                        
    <p class="visually-hidden" id="block-socialmedia-menu" class="lead">Social Media</p>
    

                              <ul data-block-uuid="5d1642a9-9f5b-4bed-9f56-6157a76875d1" class="menu vertical">
                                                                                              <li class="isSocialLink side-menu__item">
                            <a href="https://www.facebook.com/VertexPharmaInc" class="facebook" aria-label="facebook">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-facebook fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.linkedin.com/company/vertex-pharmaceuticals" class="linkedin" aria-label="linkedin">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-linkedin fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://twitter.com/VertexPharma" class="x-twitter" aria-label="x-twitter">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-x-twitter fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
                                                                                          <li class="isSocialLink side-menu__item">
                            <a href="https://www.youtube.com/channel/UCrNu_QIE9exwVQnWKgr1toQ/featured" class="youtube" aria-label="youtube">
                  <span class="fa-stack"><i class="fa fa-circle fa-stack-2x"></i><i class="fa fa-youtube fa-stack-1x fa-inverse"></i></span>
                </a>
                              </li>
          </ul>
  


    </div>

                    </div>
                </div>
                                <div class="column primary footer-global">
                    <div class="row">
                                                <div class="medium-6 columns">
                                                        <div class="region region-footer">
                                <nav role="navigation" aria-labelledby="block-footerbottom-menu" class="block--system-menu-blockfooter-bottom block--system-menu-blockfooter-bottom--5986 block--footer--system-menu-block--footer-bottom block--footer--system-menu-block--footer-bottom--5986 block--e172c75d-9834-4259-9057-aa69edfb5161 block--e172c75d-9834-4259-9057-aa69edfb5161--5986 block block-menu navigation block-system-menublock menu--footer-bottom">
                                    <ul data-block-uuid="e172c75d-9834-4259-9057-aa69edfb5161" class="menu side-menu">
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/international-privacy" target="_blank">Privacy Policy</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <a href="https://www.vrtx.com/terms-and-conditions" target="_blank">Terms of Use</a>
                                        </li>
                                        <li class="side-menu__item">
                                            <!-- OneTrust Cookies Settings button start -->
                                            <a id="ot-sdk-btn" class="ot-sdk-show-settings">Your Privacy Choices</a>
                                            <!-- OneTrust Cookies Settings button end -->
                                        </li>
                                        <li>
                                            <img src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/images/privacyoptions.svg" style="width:25px">
                                        </li>
                                    </ul>
                                </nav>
                            </div>
                        </div>
                        
                        <div class="medium-6 columns">
                            <ul class="menu float-right">
                                <li class="menu-text">Copyright &copy; 2025</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </footer>


        </div> <!-- /off-canvas-content -->

        <div class="js-off-canvas-exit"></div>


    </div> <!-- /off-canvas-wrapper-inner -->
</div> <!-- /off-canvas-wrapper -->
  </div>

    
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/5816","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","currentQuery":{"items_per_page_toggle":"1","page":"5"}},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyVUlFuwzAIvVAUa_3ZAXaCaQewiI06VhsqIG1z-zpOpa1TN22yhB_P8IzBTBonMAzcACVhG_gr5SJlAu1kOmAmF40ZvK2poIVP2EMq6AG9B8SpSDoEYCiLeVRw4n0TbjrvoP6ncItd-4fYisBRMUmtyI0n4V-1H7Ljmg6c_5Vj3uzrLH4rbS5OtTUHwr3bT4-w33q5ghE-4BIh55gKmEUoqL717kh59_S8C3JCVcqbdL9pe1X45m9VvKzwzZfS2tUzzjgZOUYWp9Qm9IAbb_ugkOkSCywyu4U7b7A2Bqxh_QnDifBsoduxSp4LXgFrIOEu","theme":"nir_pid2172","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"45e7a25462df2b241c7eec49f3c8a237acab787c5b520da38b10415af90811be"}}</script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery-2.1.4.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/jquery.circliful.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/ndq-functions.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/foundation.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/vivus.min.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/dist/js/theme-embedded-2.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/themes/site/nir_pid2172/js/modal-video.run.js?ssxojg"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_yoTi3ajw4iS9VMtHeeJMhx7zxXd9S5AacrChSDHVlFQ.js?scope=footer&amp;delta=9&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>
<script src="/core/assets/vendor/ckeditor5/ckeditor5-dll/ckeditor5-dll.js?v=41.3.1"></script>
<script src="/profiles/nasdaqir/modules/custom/nir_ckeditor_datatables/js/build/datatables.js?v=1.10.9"></script>
<script src="/sites/g/files/knoqqb74911/files/js/js_GZWqVv5lmgvMD-78CCnz6GUVTpAe1Qj92_PpS3CTNZA.js?scope=footer&amp;delta=12&amp;language=en&amp;theme=nir_pid2172&amp;include=eJyVj0sOwjAMRC-EEtENB-AEiANETmIV0zSuEpfP7UldJATqBmXh8ctY9mQqLgwYSbi4CNKeT1jtR-5ys4xzEhqbDex3q78eKioX5uShKJwodvtDZ_mGpVBEhXf0lQRdZqHQ1mww867qr8JhcOECRexPb1QfF3mWZ6Lcr5dCGVA0ivOpOewmNYHHEXL8a0Y3nmaWNcwE_Rp7EQau8HAQowsJanWQsEh9AVtyirg"></script>

    <!-- Adobe Omniture JS Rewrite -->
<script type="text/plain" class="optanon-category-C0004">var s_CCSWebHostingAccount = "trcgvertex";</script>
<script src="//assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" type="text/plain" class="optanon-category-C0004"></script>
  </body>
</html>
